Maplight Therapeutics, INC. (MPLT) — SEC Filings
Latest SEC filings for Maplight Therapeutics, INC.. Recent 144 filing on Apr 15, 2026. AI-decoded analysis of earnings, risk factors, and insider trades.
View Maplight Therapeutics, INC. on SEC EDGAR
Overview
Maplight Therapeutics, INC. (MPLT) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a S-8 filed on Mar 26, 2026: MapLight Therapeutics, Inc. filed an S-8 on March 26, 2026, to register securities for its employee benefit plans. This filing allows the company to issue shares to employees, which is a common way to attract and retain talent. For investors, this means potential dilution as more shares could be iss
Sentiment Summary
Across 8 filings, the sentiment breakdown is: 1 bearish, 4 neutral, 3 mixed. The dominant filing sentiment for Maplight Therapeutics, INC. is neutral.
Filing Type Overview
Maplight Therapeutics, INC. (MPLT) has filed 1 144, 1 S-8, 1 10-K, 2 8-K, 1 10-Q, 1 S-1/A, 1 S-1 with the SEC between Sep 2025 to Apr 2026.
Filings by Year
Recent Filings (8)
- 144 Filing — 144 · Apr 15, 2026
-
MapLight Therapeutics Files S-8 for Employee Stock Plans
— S-8 · Mar 26, 2026
MapLight Therapeutics, Inc. filed an S-8 on March 26, 2026, to register securities for its employee benefit plans. This filing allows the company to issue share -
MapLight's Lead Drug Nears Key Phase 2 Readouts for Schizophrenia, ADP
— 10-K · Mar 26, 2026 Risk: high
MapLight Therapeutics, Inc. (MPLT) is a clinical-stage biopharmaceutical company focused on CNS disorders, reporting no commercialized products and a limited op -
MapLight Therapeutics Files 8-K on Financial Results & Reg FD Disclosure
— 8-K · Mar 26, 2026
MapLight Therapeutics, Inc. filed an 8-K on March 26, 2026, reporting under Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation -
MapLight's R&D Soars, IPO Fuels Future Clinical Trials
— 10-Q · Dec 4, 2025 Risk: medium
MapLight Therapeutics, Inc. (MPLT) reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $81.6 million, up from $56 -
MapLight Therapeutics Files 8-K
— 8-K · Oct 29, 2025 Risk: medium
MapLight Therapeutics, Inc. filed an 8-K on October 29, 2025, reporting on events as of October 26, 2025. The filing indicates unregistered sales of equity secu -
MapLight Targets $250M IPO for CNS Pipeline, Schizophrenia Drug Leads
— S-1/A · Oct 6, 2025 Risk: high
MapLight Therapeutics, Inc. (MPLT) is launching its initial public offering of 14,750,000 shares at $17.00 per share, aiming to raise $250,750,000 before underw -
MapLight Therapeutics Files S-1 for IPO, Eyes CNS Market with Two Phase 2 Assets
— S-1 · Sep 19, 2025 Risk: high
MapLight Therapeutics, Inc. (MPLT) is a clinical-stage biopharmaceutical company focused on CNS disorders, filing an S-1 for its initial public offering. The co
Risk Profile
Risk Assessment: Of MPLT's 5 recent filings, 3 were flagged as high-risk, 2 as medium-risk, and 0 as low-risk. The overall risk profile suggests elevated risk that warrants close monitoring.
Financial Highlights
Key financial metrics from Maplight Therapeutics, INC.'s most recent 10-K filing (Mar 26, 2026):
- Revenue: $0
- Net Income: $-XX,XXX,XXX
- EPS: $-X.XX
- Debt-to-Equity: N/A
- Cash Position: $XX,XXX,XXX
- Operating Margin: N/A
- Total Assets: $XX,XXX,XXX
- Total Debt: $0
Key Executives
- Christopher A. Kroeger, M.D.
- Karl Deisseroth, M.D., Ph.D.
- Robert Malenka, M.D., Ph.D.
Industry Context
The biopharmaceutical industry, particularly in the CNS disorder space, is characterized by high R&D costs, long development timelines, and significant regulatory hurdles. Companies like MapLight Therapeutics compete with both large, established pharmaceutical firms and smaller, innovative biotech companies. Key trends include the increasing focus on precision medicine, the development of novel therapeutic modalities, and the growing demand for treatments for neurodegenerative diseases and psychiatric conditions.
Top Tags
Biotechnology (4) · CNS Disorders (4) · Clinical Stage (3) · Schizophrenia (3) · IPO (3) · Alzheimer's Disease Psychosis (2) · employee-benefits (1) · stock-compensation (1) · dilution (1) · regulatory-filing (1)
Key Numbers
- target enrollment for ZEPHYR Phase 2 trial: 300 — expected by April 2026
- fiscal year ended: 2026 — December 31, 2025
- shares of Voting Common Stock outstanding: 42,436,326 — as of March 19, 2026
- healthy participants enrolled in Phase 1 trials: 270 — for ML-007
- doses of ML-007 administered: 1,500 — in Phase 1 trials
- people globally affected by schizophrenia: 20 million — significant market opportunity
- people in the United States affected by schizophrenia: 3 million — significant market opportunity
- Alzheimer's patients experiencing psychosis: 40% — out of 7 million in the US
- Net Loss: $81.6M — for the nine months ended September 30, 2025, up 44.8% from $56.35M in 2024
- Research and Development Expenses: $73.73M — for the nine months ended September 30, 2025, up 54.2% from $47.81M in 2024
- Net Proceeds from IPO: $262.3M — received in October 2025, post-quarter
- Net Proceeds from Concurrent Private Placement: $7.5M — received in October 2025, post-quarter
- Accumulated Deficit: $281.0M — as of September 30, 2025
- Cash and Cash Equivalents: $64.15M — as of September 30, 2025, up from $38.25M at December 31, 2024
- Total Assets: $257.22M — as of September 30, 2025, up from $136.92M at December 31, 2024
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Maplight Therapeutics, INC. (MPLT)?
Maplight Therapeutics, INC. has 8 recent SEC filings from Sep 2025 to Apr 2026, including 2 8-K, 1 144, 1 S-8. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of MPLT filings?
Across 8 filings, the sentiment breakdown is: 1 bearish, 4 neutral, 3 mixed. The dominant sentiment is neutral.
Where can I find Maplight Therapeutics, INC. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Maplight Therapeutics, INC. (MPLT) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Maplight Therapeutics, INC.?
Key financial highlights from Maplight Therapeutics, INC.'s most recent 10-K include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for MPLT?
The investment thesis for MPLT includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Maplight Therapeutics, INC.?
Key executives identified across Maplight Therapeutics, INC.'s filings include Christopher A. Kroeger, M.D., Karl Deisseroth, M.D., Ph.D., Robert Malenka, M.D., Ph.D..
What are the main risk factors for Maplight Therapeutics, INC. stock?
Of MPLT's 5 assessed filings, 3 were flagged high-risk, 2 medium-risk, and 0 low-risk.
What are recent predictions and forward guidance from Maplight Therapeutics, INC.?
Forward guidance and predictions for Maplight Therapeutics, INC. are extracted from SEC filings as they are enriched.